Acute Optic Neuritis

KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Riad Sherif, MD, CEO of Oculis, discusses data on OCS-05 for the treatment of acute optic neuritis.

OCS-05 met safety and efficacy endpoints in the treatment of acute optic neuritis in a phase 2 trial, according to a press release from Oculis.

Oculis has completed the first patient visit in its phase 3 OPTIMIZE-2 trial of OCS-01, the company’s preservative-free, once-daily topical formulation of dexamethasone for treating pain and inflammation after cataract surgery.